Sun Pharma Q2 net falls 46.5 pct on Protonix provision
MUMBAI (Reuters) - Sun Pharmaceutical Industries (SUN.NS) reported a 46.5 percent drop in quarterly net profit after it set aside 5.84 billion rupees towards a possible compensation in a patent dispute case related to drug Protonix.
The Mumbai-based drugmaker said consolidated net profit fell to 3.2 billion rupees during fiscal second quarter ended September from 5.98 billion rupees a year earlier. Net sales rose 40.2 percent to 26.57 billion rupees.
Analysts had estimated the net profit at 7.68 billion rupees, according to Thomson Reuters I/B/E/S. (Reporting by Kaustubh Kulkarni; Editing by Jijo Jacob)
- Tweet this
- Share this
- Digg this
- Indiana police charge suspect who may have killed for decades
- Oil falls below $86 as oversupply, global economy worries weigh
- Total CEO de Margerie killed in Moscow business jet accident
- UPDATE 7-Total CEO de Margerie killed in Moscow business jet accident
- UPDATE 2-Texas investor Sam Wyly files for bankruptcy after losing SEC fraud case
China grew at its slowest pace since the global financial crisis in the September quarter and risks missing its official target for the first time in 15 years, adding to concerns the world's second-largest economy is becoming a drag on global growth. Full Article
Total CEO de Margerie killed in Moscow plane accident - airport spokeswoman. Full Article